Clinical Significance of the New Cardiovascular Risk Markers in Diabetes Mellitus

被引:2
作者
Iglesias, Pedro [1 ]
Pedro-Botet, J. [2 ]
Arrieta, Francisco [1 ]
Aguilar, Manuel [3 ]
Escobar, Fernando [4 ]
机构
[1] Hosp Ramon & Cajal, Dept Endocrinol & Nutr, Ctra Colmenar,Km 9,100, E-28034 Madrid, Spain
[2] Hosp del Mar, Dept Endocrinol & Nutr, Barcelona, Spain
[3] Hosp Puerta del Mar, Dept Endocrinol & Nutr, Cadiz, Spain
[4] Hosp Clin, Dept Endocrinol & Nutr, Granada, Spain
关键词
Inflammatory markers; anti-inflammatory markers; bone markers; cardiovascular disease; cardiovascular mortality; diabetes mellitus;
D O I
10.2174/1573399811666150319112319
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of type 2 diabetes mellitus (T2DM) has risen in recent decades, and cardiovascular disease (CVD) remains the leading cause of death in this population. Several studies have shown that, in clinical practice, identifying diabetic patients at high risk for CVD is essential, since these patients benefit from aggressive strategies to achieve a greater risk reduction. In recent years, new markers of CV risk have been added to the list of those already known. These new emerging markers, such as inflammatory, bone and hormonal markers, act as new indicators of subclinical atherosclerosis and CV mortality. Therefore, we reviewed the ongoing scientific research on these new biomarkers and discuss their clinical impact on the identification of T2DM patients at high CV risk.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 90 条
  • [1] Interleukin-1 Receptor Antagonist: A New Therapy for Type 2 Diabetes Mellitus
    Akash, Muhammad Sajid Hamid
    Shen, Qi
    Rehman, Kanwal
    Chen, Shuqing
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (05) : 1647 - 1658
  • [2] Standards of Medical Care in Diabetes-2014
    不详
    [J]. DIABETES CARE, 2014, 37 : S14 - S80
  • [3] Apostolakis Stavros, 2008, Cardiovascular & Hematological Agents in Medicinal Chemistry, V6, P150, DOI 10.2174/187152508783955006
  • [4] Comparison of serum high-molecular weight (HMS adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin
    Aso, Yoshimasa
    Yamamoto, Ruriko
    Wakabayashi, Sadao
    Uchida, Toshihiko
    Takayanagi, Kan
    Takebayashi, Kohzo
    Okuno, Takehiko
    Inoue, Teruo
    Node, Koichi
    Tobe, Takashi
    Inukai, Toshihiko
    Nakano, Yasuko
    [J]. DIABETES, 2006, 55 (07) : 1954 - 1960
  • [5] Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patients
    Bar-Shalom, Dana
    Poulsen, Mikael K.
    Rasmussen, Lars M.
    Diederichsen, Axel C. P.
    Sand, Niels P. R.
    Henriksen, Jan E.
    Nybo, Mads
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2014, 11 (06) : 448 - 450
  • [6] Screening for coronary artery disease in patients with diabetes
    Bax, Jeroen J.
    Young, Lawrence H.
    Frye, Robert L.
    Bonow, Robert O.
    Steinberg, Helmut O.
    Barrett, Eugene J.
    [J]. DIABETES CARE, 2007, 30 (10) : 2729 - 2736
  • [7] Bjerre M, 2014, SCAND J CLIN LAB INV, P1
  • [8] Mechanisms of disease:: Role of transforming growth factor β in human disease.
    Blobe, GC
    Schiemann, WP
    Lodish, HF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (18) : 1350 - 1358
  • [9] The role of TNF-α in insulin resistance
    Borst, SE
    [J]. ENDOCRINE, 2004, 23 (2-3) : 177 - 182
  • [10] TNF-mediated inflammatory disease
    Bradley, J. R.
    [J]. JOURNAL OF PATHOLOGY, 2008, 214 (02) : 149 - 160